Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204298 | 0.89 | TGM2 (0.71) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL3656920 | 0.84 | HTT (0.68) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL485753 | 0.83 | TGM2 (0.66) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL735886 | 0.82 | HTT (0.68) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL22163638 | 0.82 | TGM2 (0.61) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.81 | HTT (0.81) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL7064121 | 0.81 | TGM2 (0.63) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL28612192 | 0.81 | HTT (0.67) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL7064126 | 0.81 | TGM2 (0.63) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL17752539 | 0.80 | TGM2 (0.66) | TGM2HTTLMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TGM2 301/4885HTT 432/4885LMNA 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.